ClinicalTrials.gg
CompletedNCT05725902Updated Apr 8, 2026

Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease

A Phase 2 interventional study of Etavopivat in Sickle Cell Disease, sponsored by Novo Nordisk A/S. Completed at 1 site in United States. Open to participants aged 12 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
12 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Anemia, Sickle Cell by Novo Nordisk A/S — 4 open to participants now, 5 under way, 3 of them phase 3. Anemia, Sickle Cell · Novo Nordisk A/S.

Enrollment
11th of 11
12 · median 95
Started
2024
with 1 other
Phase 2
5 of 11
2 open now
Registered
5th of 11
by date

Among the 11 studies in Anemia, Sickle Cell by Novo Nordisk A/S, this one is the 11th largest by enrollment, is one of 2 that started in 2024, is one of 5 in phase 2, and was the 5th registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

4 of the 11 studies in Anemia, Sickle Cell by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 12 Years to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Anemia, Sickle Cell by Novo Nordisk A/S, or all of them as a file.
02

Study summary

An open-label, single arm study in patients 12 to 21 years of age with SCD to evaluate the effects of etavopivat on cerebral and muscle hemodynamics.

Read the detailed description

This study is a pilot, open-label, single-arm study to evaluate the effect of etavopivat on cerebral hemodynamics, as measured by frequency domain near-infrared spectroscopy/diffuse correlation spectroscopy (FDNIRS/DCS) in participants 12 to 21 years of age with sickle cell disease (SCD). Cerebral blood flow (CBF), oxygen ejection fraction (OEF), and cerebral metabolic rate of oxygen (CMRO2) will be assessed FDNIRS/DCS in participants prior to, periodically throughout, and after 24 weeks of treatment with etavopivat. Approximately 12 participants will be enrolled.

The duration of study treatment will be 24 weeks. The study duration for individual participants may last up to 36 to 38 weeks and includes the Screening Period (up to 4 weeks before study treatment), the 24-week treatment period, a Safety Follow-up Visit at 4 weeks (+ 7 days) after the last dose of study drug, and an End of Study (EOS) visit approximately 8 weeks (± 7 days) after the last dose of study drug. A participant is considered to have completed the study if he or she has completed all phases of the study including the last visit or the last scheduled procedure shown in the Schedule of Events.

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

04

Who can participate

Ages eligible
12 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Homozygous SS (HbSS) or hemoglobin S/beta0 thalassemia (HbS/β0 thal)
  • Hemoglobin (Hb): Hb ≤ 9.0 g/dL at baseline
  • Concomitant hydroxyurea (HU) therapy is allowed if the dose has been stable for at least 3 months with no anticipated need for dose adjustments during the study and no sign of hematological toxicity

Exclusion criteria

Exclusion Criteria:

  • Any one of the following requiring a medical facility visit within 14 days prior to signing the form:

    • Vaso-occlusive crisis (VOC)
    • Acute chest syndrome (ACS)
    • Splenic sequestration
    • Dactylitis
  • Requires chronic transfusion therapy
  • Abnormal TCD in the last 12 months
  • RBC transfusion within 60 days of screening
  • Severe renal dysfunction at the Screening Visit or on chronic dialysis
  • Hepatic dysfunction
  • cardiac or pulmonary disease- e.g., congenital heart defect, uncompensated heart failure, or any unstable cardiac condition, arrhythmic heart condition, pulmonary fibrosis, pulmonary hypertension
  • Major surgery involving the stomach or small intestine
  • Chemotherapy or radiation within the past 2 years
  • History of overt clinical stroke within previous 2 years or any history of an intracranial hemorrhage
  • Clinically significant bacterial, fungal, parasitic, or viral infection currently receiving or that will require therapy
  • Female who is breast feeding or pregnant
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Etavopivat

    Single-arm, open-label

    Drug: Etavopivat

Interventions

  • The study intervention is etavopivat (400 mg), administered orally and once daily (QD)

    Also known as: FT-4202

06

What researchers measure

Primary outcomes

  1. Effect of etavopivat on cerebral blood flow (CBF)

    Change in cerebral blood flow (CBF) assessments from baseline will be summarized with descriptive statistics by nominal study visit.

    Time frame: 24 weeks

  2. Effect of etavopivat on oxygen ejection fraction (OEF)

    Change in OEF assessments from baseline will be summarized with descriptive statistics by nominal study visit.

    Time frame: 24 weeks

  3. Effect of etavopivat on cerebral metabolic rate of oxygen (CMRO2)

    Change in CMRO2 assessments from baseline will be summarized with descriptive statistics by nominal study visit.

    Time frame: 24 weeks

Secondary outcomes

  1. Relationship between CBF and change in Hb levels

    The change from baseline of CBF will be correlated to the corresponding post-baseline assessment for change in Hb.

    Time frame: 24 weeks

  2. Relationship between oxygen ejection fraction (OEF) and change in Hb levels

    The change from baseline of OEF will be correlated to the corresponding post-baseline assessment for change in Hb.

    Time frame: 24 weeks

  3. Relationship between cerebral metabolic rate of oxygen (CMRO2) and change in Hb levels

    The change from baseline of CMRO2 will be correlated to the corresponding post-baseline assessment for change in Hb.

    Time frame: 24 weeks

  4. Adverse events in participants with SCD

    Maximum intensity of treatment emergent adverse events (TEAEs) will be summarized by system organ class and preferred term. The tabulation of deaths, serious TEAEs, serious drug-related TEAEs and TEAEs leading to study drug discontinuation will also be provided

    Time frame: 24 weeks

  5. Muscle hemodynamic effect of etavopivat on muscle blood flow

    Change in muscle blood flow assessments from baseline will be summarized with descriptive statistics by nominal study visit.

    Time frame: 24 weeks

  6. Muscle hemodynamic effect of etavopivat on oxygen ejection fraction (OEF)

    Change in OEF from baseline will be summarized with descriptive statistics by nominal study visit.

    Time frame: 24 weeks

  7. Muscle hemodynamic effect of etavopivat on cerebral metabolic rate of oxygen (CMRO2)

    Change in CMRO2 from baseline will be summarized with descriptive statistics by nominal study visit.

    Time frame: 24 weeks

07

Study locations

1 site
  • Emory University Children's Healthcare of Atlanta
    Atlanta, Georgia 30342, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Mar 2026, 24 months.

Of 34 industry-sponsored phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 41. This study's 24 months is below that.

Counting every sponsor, half of 93 studies reached it within 46 months; a quarter within 24 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2023
First posted
Feb 13, 2023
StartActual
Mar 9, 2024
Primary completionActual
Mar 9, 2026
CompletionActual
Mar 9, 2026
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05725902
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 13, 2023
Start date
Mar 9, 2024
Primary completion
Mar 9, 2026
Completion
Mar 9, 2026
Last update
Apr 8, 2026

Study contacts

Clinical Transparency dept. 2834
study director · Novo Nordisk A/S
Amy Tang, MD
principal investigator · Children's Healthcare of Atlanta

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etavopivat

Start the discussion